PDUFA V Late-Cycle Review Meetings Need Limited Focus, FDA Says
This article was originally published in The Pink Sheet Daily
Agency staff are concerned that mandatory meetings with NME/novel biologic sponsors late in the review cycle will result in a forum for extensive debate and a flood of new submissions and appeals, Office of New Drugs Director Jenkins said at Elsevier Business Intelligence’s FDA/CMS Summit.
You may also be interested in...
OND Director John Jenkins says the late-cycle meeting in the new PDUFA review model will offer a lot of information to sponsors, but likely will not be predictive of application approvability.
Phase III study in newly diagnosed patients with NPM1-mutated AML could enable Kronos’ SYK-inhibitor to reach market two years earlier under accelerated approval than it would under a traditional endpoint, company says.
Agency’s unusual public statement about an investigational product's development status may be aimed at countering bullish comments from the sponsor; FDA cites failure of pivotal trial on the primary and secondary endpoints and ‘modest excess in deaths’ with the cell therapy.